

Company release No 6/2013

Hørsholm
5 March 2013

**ALK's Board of Directors proposes new board member
at the Annual General Meeting on 12 March 2013**

Page 1/1

At the Annual General Meeting to be held on 12 March 2013, ALK's Board of Directors proposes Jakob Riis for new election to the Board. Jakob Riis (46) is Executive Vice President Marketing & Medical Affairs at Novo Nordisk. Jakob Riis is recommended as an independent member of the Board in accordance with point 5.4.1 of the Danish Recommendations on Corporate Governance.

Steen Riisgaard, Chairman of the Board says: "We look very much forward to working together with Jakob Riis. His extensive experience in global launches of pharmaceutical products can contribute to the global success of the new allergy immunotherapy products which ALK expects to launch in the coming years."

The recommendation is a result of Lars Holmqvist not seeking re-election due to heavy work load and extensive travelling. Lars Holmqvist who has been a member of ALK's Board of Directors since 2010, was Vice Chairman from 2011-12 and Chairman of the Audit Committee from 2011-13.

Steen Riisgaard says: "I would like to thank Lars Holmqvist for his significant contribution to the Board's work during the last three years, especially his contribution to the two most recent strategies for ALK's development. A development that will ensure considerable growth in ALK's sales and earnings in the coming years."

As can be seen in the Notice convening the Annual General Meeting (company release No 5 dated 14 February 2013), all members of the Board of Directors are up for election. The Board of Directors proposes re-election of the other Board members elected by shareholders at the annual general meeting: Steen Riisgaard, Christian Dyvig, Thorleif Krarup, Anders Gersel Pedersen og Jes Østergaard.

ALK-Abelló A/S

Steen Riisgaard
Chairman

For further information please contact:

Jens Bager, President and CEO, tel. +45 4574 7576

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Press: Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143